BIG
SUPN icon

Brooklyn Investment Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Brooklyn Investment Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
4,159
+243
+6% +$12.4K 0.01% 1665
2025
Q4 		$201K Buy
+3,916
New +$190K 0.01% 1378
2025
Q3 		– Sell
-828
Closed -$26.1K – 2440
2025
Q2 		$26.1K Buy
828
+606
+273% +$19.4K ﹤0.01% 1704
2025
Q1 		$7.27K Buy
222
+187
+534% +$6.63K ﹤0.01% 1666
2024
Q4 		$1.27K Buy
+35
New +$1.23K ﹤0.01% 1567

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brooklyn Investment Group's SUPN Position: Q1 2026 in Review

Brooklyn Investment Group increased its Supernus Pharmaceuticals (SUPN) stake by 6.2% in Q1 2026, buying an estimated $12.4K and bringing the position to 4,159 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #1665.

Brooklyn Investment Group first reported a position in SUPN in Q4 2024 and has held it in 5 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Brooklyn Investment Group held 4,159 shares of Supernus Pharmaceuticals worth $215K as of Q1 2026.
  • Brooklyn Investment Group bought 243 Supernus Pharmaceuticals shares in Q1 2026, an estimated $12.4K.
  • Supernus Pharmaceuticals made up 0.01% of Brooklyn Investment Group's portfolio in Q1 2026, its #1665 holding.
  • Brooklyn Investment Group first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.